CoChat

Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Purpose: The epidermal growth factor receptor (EGFR) is a key regulator of growth, differentiation, and survival of epithelial cancers. In a small subset of tumors, the presence of activating mutations within the ATP binding site confers increased susceptibility to gefitinib, a potent tyrosine kinase inhibitor of EGFR. Agents that can inhibit EGFR function through different mechanisms may enhance gefitinib activity in patients lacking these mutations. Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies. Experimental Design: In this study, we evaluated the effect of lovastatin on EGFR function and on gefitinib activity. Effects on EGFR function were analyzed by Western blot analysis using phosphospecific antibodies to EGFR, AKT, and extracellular signal-regulated kinase. Cytotoxic effects of lovastatin and/or gefitinib were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and flow cytometry. Results: Lovastatin treatment inhibited EGF-induced EGFR autophosphorylation by 24 hours that was reversed by the coadministration of mevalonate. Combining lovastatin and gefitinib treatments showed enhanced inhibition of AKT activation by EGF in SCC9 cells. The combination of 10 μmol/L lovastatin and 10 μmol/L gefitinib treatments showed cooperative cytotoxicity in all 8 squamous cell carcinomas, 4 of 4 non–small cell lung carcinoma and 4 of 4 colon carcinoma cell lines tested. Isobologram and flow cytometric analyses of three representative cell lines with wild-type EGFR ATP binding sites confirmed that this combination was synergistic inducing a potent apoptotic response. Conclusions: Taken together, these results show that targeting the mevalonate pathway can inhibit EGFR function. They also suggest the potential utility of combining these clinically relevant therapeutic approaches.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-1951

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 107

Metadata

Authors
Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J.
Affiliations
  • 1Centre for Cancer Therapeutics and
  • 2Medical Oncology,
  • University of Ottawa (CA)
Venue
Clinical Cancer Research
Published
2005-03-15
Volume
11
Issue
6
Pages
2398-2407
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2113341349
Cited by
101
References
35
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 6 · 2017: 6 · 2016: 6 · 2015: 7 · 2014: 5 · 2013: 7 · 2012: 5
FWCI
1.97
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
AstraZeneca
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
mevalonate pathway, epidermal growth factor receptor, lovastatin, gefitinib, combination therapy, EGFR autophosphorylation, Akt activation, squamous cell carcinoma, non-small cell lung cancer, colon cancer, apoptosis, drug synergy, mevalonate
MeSH terms
Gefitinib, Adenosine Triphosphate, Antineoplastic Combined Chemotherapy Protocols, Binding Sites, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Colonic Neoplasms, Drug Synergism, Enzyme Inhibitors, Epidermal Growth Factor, Humans, Lovastatin, Lung Neoplasms, Mevalonic Acid, Mutation, Phosphorylation, Quinazolines, Tumor Cells, Cultured, Signal Transduction, Apoptosis, Mitogen-Activated Protein Kinases, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1951
The paper
Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J. (2005). Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1951

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.